Message to the Arrhythmogenic Cardiomyopathy Community

LX2020 Program Update – Lexeo Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020

August 6, 2026

Dear Advocacy Partners and PKP2-ACM community members,

We are pleased to share an update on LX2020, our investigational gene therapy for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Lexeo has received U.S. Food and Drug (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020.

Highlights:

- The FDA's decision was based on interim clinical data from the ongoing Phase I/II clinical trial of LX2020 (HEROIC-PKP2).
- RMAT designation is an FDA program that helps speed the development and review of promising therapies for serious conditions, providing additional FDA guidance and potentially faster review pathways as research progresses.
- This is an encouraging milestone for the LX2020 program. RMAT designation recognizes the potential of LX2020 as a gene therapy that may address the underlying genetic cause of PKP2-ACM.

Next steps for the LX2020 program:

- We anticipate sharing clinical and regulatory updates before the end of the year.

We are grateful to the individuals living with PKP2 ACM, their families, caregivers, investigators, and advocacy partners whose contributions have helped make important milestones like this possible. We remain committed to working alongside the community as development of LX2020 continues.

The Lexeo Team